An Integrated Method for Reproducible and Accurate Image-Guided Stereotactic Cranial Irradiation of Brain Tumors Using the Small Animal Radiation Research Platform  by Baumann, Brian C. et al.
An Integrated Method for
Reproducible and Accurate
Image-Guided Stereotactic
Cranial Irradiation of
Brain Tumors Using the
Small Animal Radiation
Research Platform1
Brian C. Baumann, Joseph L. Benci,
Phillip P. Santoiemma, Sanjay Chandrasekaran,
Andrew B. Hollander, Gary D. Kao and Jay F. Dorsey
Department of Radiation Oncology and the Division
of Radiobiology, Perelman School of Medicine at
the University of Pennsylvania, Philadelphia, PA
Abstract
Preclinical studies of cranial radiation therapy (RT) using animal brain tumor models have been hampered by tech-
nical limitations in the delivery of clinically relevant RT. We established a bioimageable mouse model of glioblastoma
multiforme (GBM) and an image-guided radiation delivery system that facilitated precise tumor localization and treat-
ment and which closely resembled clinical RT. Our novel radiation system makes use of magnetic resonance
imaging (MRI) and bioluminescent imaging (BLI) to define tumor volumes, computed tomographic (CT) imaging
for accurate treatment planning, a novel mouse immobilization system, and precise treatments delivered with the
Small Animal Radiation Research Platform. We demonstrated that, in vivo, BLI correlated well with MRI for defining
tumor volumes. Our novel restraint system enhanced setup reproducibility and precision, was atraumatic, and
minimized artifacts on CT imaging used for treatment planning. We confirmed precise radiation delivery through
immunofluorescent analysis of the phosphorylation of histone H2AX in irradiated brains and brain tumors. Assays
with an intravenous near-infrared fluorescent probe confirmed that radiation of orthografts increased disruption of
the tumor blood-brain barrier (BBB). This integrated model system, which facilitated delivery of precise, reproduc-
ible, stereotactic cranial RT in mice and confirmed RT’s resultant histologic and BBB changes, may aid future brain
tumor research.
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Introduction
Glioblastoma multiforme (GBM) is a primary brain cancer with a
median survival of only 14.6 months despite standard multimodality
treatment with surgical resection, postoperative RT, and temozolomide
chemotherapy [1]. New therapeutic approaches are urgently needed to
improve patient survival and quality of life. The development of new
treatment strategies is limited in part by the quality of preclinical animal
models of GBM and by preclinical RT techniques that have lagged far
behind current clinical practice.
Until recently, animal irradiation was typically conducted using fixed
radiation sources applying a single radiation field. Sparing of normal
tissue was usually achieved with lead shielding to cover the animal while
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exposing the areas to be treated. The accuracy of dosimetric calcula-
tions was limited, and the ability to target a treatment volume precisely
remained largely beyond the reach of these simple techniques. The
recent development of three-dimensional conformal small animal micro-
irradiator systems has been a major step forward [2–4]. One such system
developed at Johns Hopkins University is the Small Animal Radiation
Research Platform (SARRP), an image-guided x-ray microirradiator
with an onboard high-resolution CT scanner that can deliver non-
coplanar radiation to an anatomic target with precision [3].
We sought to establish an animal model system that more accu-
rately reflects current clinical practice by coupling the SARRP’s precise
radiation delivery with imaging techniques that can accurately localize
targets and then apply these sophisticated techniques to orthotopic,
bioimageable GBM implants in mice that closely mimic the clinical
characteristics of human GBM tumors. In this article, we describe
our animal model for GBM and our RT techniques, including a novel
CT-compatible immobilization system that we designed and con-
structed for focal brain irradiation that ensures day-to-day reproducibil-
ity without trauma to the animal. We further describe histologic and
imaging techniques to verify the treatment accuracy of the delivered
radiation, and the ensuing effects on disrupting the blood-brain barrier
(BBB) of the targeted brain tumor.
Materials and Methods
All animal experiments were performed in accordance with Institu-
tional Animal Care and Use Committee guidelines under the terms of
an Institutional Animal Care and Use Committee–approved protocol.
Mouse Model of GBM
Labeling tumor cells to express firefly luciferase and green fluorescent
protein. The human-derived GBM tumor cell line U251 was trans-
duced with a lentiviral construct (pGreenFire; System Biosciences,
Mountain View, CA) containing the firefly luciferase gene and the
green fluorescent protein (GFP) gene under the control of a spleen focus-
forming virus promoter. About 200,000 cells were plated and washed
with phosphate-buffered saline (PBS). Thawed viral particles in 250 μl
of Dulbecco modified Eagle medium were added to the cells. Cells were
incubated for 72 hours. After transfection, supernatant with virus was
collected and passed through a 22-nm filter. The filtered supernatant
was used to infect the target U251 cells. The transduced U251 cells were
sorted twice with flow cytometry to select the 1% of cells with the greatest
fluorescence for propagation in culture and for implantation as xenograft
tumors in nude mice.
Intracranial implantation of tumor cells. Nude athymic NCr
mice (nu/nu) were weighed and premedicated 1 hour before intracranial
implantation with a subcutaneous injection of 5 mg/kg of meloxicam
in saline to control for postoperative pain and inflammation. The mice
were anesthetized with an intraperitoneal injection of ketamine/xylazine
at doses of 140 and 10 mg/kg, respectively. Once the anesthesia extin-
guished the mouse’s response to light pinching of the rear foot, the
mouse was immobilized in a stereotactic device (Stoelting Digital Just
forMice Stereotactic Instrument [Stoelting,WoodDale, IL]; Figure 1A).
The mouse’s temperature was monitored with a rectal probe and main-
tained at 37°C with feedback control to a heating plate underneath
the animal. An ophthalmic ointment was applied to prevent drying.
Using aseptic technique, the top of the head was swabbed with beta-
dine, and the skull was exposed through a 0.5-cm longitudinal scalp
incision. Using the stereotactic armature, a small hole was drilled using
the ForedomMicrodrill (Foredom, Bethel, CT) with a 0.4-mm burr at
a site 2 mm posterior and 1.5 mm lateral to the bregma in the right
cerebral hemisphere (Figure 1A). Through this hole, a stereotactically
guided syringe with a 30-gauge flat bevel needle delivered approxi-
mately 300,000 luciferase/GFP–expressing U251 human brain tumor
cells in 6 μl of Dulbecco modified Eagle medium at a depth of 2.5 mm
within the brain parenchyma at an injection rate of 0.5 μl/min using
the Automated Injector Pump by Harvard Apparatus [5]. After injec-
tion, the needle was left in the brain for a period of 2 minutes and then
slowly withdrawn. The incision was closed with bone wax, the skin was
reapproximated with glue, and the animal was moved to a heated pad
for postoperative recovery.
Bioluminescent imaging. Mice were imaged using the IVIS Lumina II
(Caliper,Hopkinton,MA) bioluminescence imaging (BLI) systembegin-
ning 1 week after tumor injection. The mice were anesthetized by intra-
peritoneal injection with ketamine/xylazine (140:10 mg/kg) before
receiving a subcutaneous injection of 60 μl of D-luciferin (50 mg/ml),
which freely crosses the BBB [6]. Imaging through the IVIS system com-
menced 5 minutes after the luciferin injection and was repeated over a
span of 30 minutes to determine the maximum luminescence intensity
in photons/second, a surrogate marker for the size of the tumor. After
image acquisition, a volume of interest was drawn around each tumor,
and a background volume of interest was selected in an area free from
tumor to generate a background-corrected bioluminescence flux value
for each tumor at each given time point. The maximum background-
corrected value for that tumor during the 30-minute imaging session
was used as the maximum bioluminescent value. The bioluminescence
of tumors was tracked over time using a measure termed fold, which
was defined as follows: [current max BLI signal]/[initial pretreatment
max BLI signal] [7,8]. IVIS imaging was repeated at least weekly to
measure tumor size.
Multimodality Imaging to Localize Tumors
Magnetic resonance imaging. T2-weighted spin-echo in vivo mag-
netic resonance imaging (MRI) was performed to determine the size
and anatomic location of the brain tumor for accurate targeting with
RT. The mice were anesthetized with 1.0% to 1.5% isoflurane in
oxygen administered at a flow rate of 1 L/min through a nose cone.
The mouse was placed in a custom-built restrainer, and the restrainer
was placed in a 20-mm radiofrequency coil (Cryogenic Preclinical
9.4-T Mouse Neuro Coil; m2m Imaging Corp, Cleveland, OH). An
MR-compatible small animal monitoring system with a rectal fiber-
optic temperature probe (SA Instruments, Stony Brook, NY) was used
to record the animal’s body temperature, which was maintained at
36.8°C by blowing warm air through the magnet bore. The mouse’s
respirations were monitored with a respiratory pillow. MRI was per-
formed on a Varian 9.4-T 31-cm horizontal-bore MR spectrometer
(Varian, Palo Alto, CA) equipped with a 21-cm ID gauss/cm and a
12-cm ID gauss/cm gradient tube and interfaced to a Varian Direct
Drive console. A localizer scan was performed followed by a T2-weighted
spin-echo scan with the following parameters: echo time = 2000 milli-
seconds, repetition time = 40 milliseconds, number of averages = 4, slice
thickness = 0.5 mm, field of view = 20 × 20 mm, and matrix = 256 ×
256 to generate high-resolution images. MR images were processed
using ImageJ software (NIH Bethesda, MD) and Amira software (Visage
Imaging, SanDiego, CA). Amira was used tomeasure tumor dimensions
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(Figure 2A), which were used to determine the collimator size and iso-
center depth for a radiation portal that would adequately encompass the
entire tumor while minimizing dose to adjacent normal tissues.
Bioluminescent imaging to confirm tumor targeting. Immediately
before radiation, intracranial tumors were imaged using BLI as pre-
viously described to determine the anatomic location of maximum
bioluminescent signal intensity by increasing the threshold of biolumi-
nescent flux until only the brightest area of signal was evident as a few
pixels (Figure 2B). This area was marked on the animal’s scalp with a
marker, and the animal was rescanned to confirm that the mark corre-
sponded to the highest BLI signal intensity, which would be used to
localize the isocenter for radiation portals.
RT stereotactic immobilization device. We designed a novel restraint
system (Figure 2C) to optimize the delivery of focused radiation beams
targeting the mouse’s intracranial xenografts. All materials were selected
so as to avoid interference with the onboard CT scanner on the SARRP
irradiator. The restraining device consisted of a fiberglass base attached
with plastic screws to the removable, fiberglass SARRP platform con-
structed by Xstrahl (Camberley, United Kingdom). Attached to the base
of the restraint is a semicircular cradle made of the phenolic compound
Garolite (McMaster-Carr, Chicago, IL), which supports the mouse and
limits its movement. An adjustable-length bite bar constructed with
Delrin (DuPont,Wilmington, DE) holds the animal’s snout in position;
this was hollowed out along its entire length to allow delivery of iso-
flurane anesthesia directly into the animal’s mouth, obviating the need
Figure 1. Establishing human-derived orthotopic GBM tumors in mice and subsequent imaging with bioluminescent and MR imaging.
(A) Stereotactic implantation of GBM cells expressing GFP and luciferase into the brains of nude mice to create orthotopic tumors.
(B) Hematoxylin/eosin staining of brains excised from mice shows the orthotopic tumor, designated within the arrows, under light micros-
copy at four different magnifications. (C) Orthotopic GBM tumors show robust expression of HIF-1α and VEGF. Normal brain (left column)
or orthotopic brain tumor tissue (right column) were sectioned, fixed onto slides, and stained for HIF-1α (top) or VEGF (middle) protein
expression. The bottom row shows expression of GFP. The immunofluorescent analyses were performed through the respective specific
primary antibodies followed by red fluorescent protein (RFP)–labeled secondary antibodies to detect the specific signal. (D) BLI shows serial
growth of the implanted tumors (representative mice shown during BLI on the specified day after initial implantation of tumor cells). Bio-
luminescence flux also reflects intracranial growth patterns. GBM cells expressing GFP and luciferase were stereotactically implanted,
followed by in vivo serial BLI of the resultant brain tumors. BLI flux was defined as photons per second per squared centimeter, which
reliably reflected intracranial growth patterns. (E) Bioluminescent imaging signal from tumors growing within the mouse correlate well with
tumor volume measured after excision. In vivo BLI signal (“Bioluminescent Max Flux”) was recorded for mice orthotopic brain tumors
immediately before sacrifice. The tumors of each mouse were then excised, and the respective volume of each tumor was manually
measured. The measured tumor volumes significantly correlate with BLI values (R2 = 0.9283).
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for a nose cone that would partially obscure the animal’s head and inter-
fere with the placement and visualization of fiducial marker landmarks
for radiation targeting. A fully adjustable ear bar system anchored the
animal’s head in position using Garolite-constructed ear bars. The height
of each ear bar could be adjusted within a range of 1.2 cm and can then
be screwed into place at the desired height on the polyvinyl chloride–
constructed ear bar towers. The ear bars were then positioned within
the ear canals using the appropriate degree of tension to immobilize the
head in a level plane without causing trauma to the animal.
Use of fiducial markers to define and confirm radiation isocenters.
Once the animal was positioned in the restrainer, a 1-mm-diameter
nylon spherical fiducial marker was attached to the scalp with tissue
glue at the spot of maximal BLI signal to serve as a guide for the selec-
tion of an isocenter during CT-guided treatment planning. Two addi-
tional nylon fiducial markers were placed lateral to the scalp fiducial
markers in the same horizontal plane. These fiducial markers were
spaced 3.5 cm apart within the field of view of the CT scanner, and
the right fiducial marker was placed 1.4 cm from the scalp fiducial.
These lateral fiducial markers appeared in the same coronal plane as
the scalp fiducial marker on treatment planning CT scans (Figure 2D)
and served as a check to ensure that the scalp fiducial marker was not
displaced during setup.
Treatment planning and delivery of image-guided RT. High-
resolution treatment planning CT scans were performed using the
SARRP’s onboard CT scanner linked to Pinnacle Treatment Planning
software (Philips, Andover, MA). An isocenter was selected using the
coronal, axial, and sagittal images produced by the CT scanner coupled
with the fiducial markers placed to show the maximum BLI signal
intensity (Figure 2D). The depth of the isocenter was previously deter-
mined based on the depth to the center of the tumor on the MRI scan.
Once the isocenter was established, a treatment plan was generated, and
the appropriately sized collimator for the radiation portal previously
determined from the MRI was loaded onto the SARRP. The mouse’s
brain tumor was irradiated with a unidirectional superior-to-inferior
Figure 2. Image-guided stereotactic delivery of radiation to implanted tumors. (A) Spin-echo MRI of a mouse intracranial tumor using a
9.4-T MR spectrometer to determine the precise anatomic localization of the xenograft. The tumor volume was contoured in pink using
the software package Amira. (B) Point of maximal bioluminescent signal for the tumor was determined (red arrow), and the spot was
tattooed to aid in the setup of radiation treatment. (C) Anesthetized mouse secured in the home-built novel stereotactic restrainer. The point
of maximal bioluminescent signal, identified previously, is covered by a fiducial marker (red arrow) to facilitate identification of the location
on CT imaging for treatment planning. (D) Treatment planning CT scans showing the coronal, axial, and sagittal views of the brain. The
small red crosses in each image indicate the selected isocenter. In the top right image, the coronal CT of the brain reveals three coplanar
fiducial markers used to confirm proper setup for treatment (the scalp fiducial marker and two lateral fiducial markers on the restrainer seen
at the bottom corners). (E) Irradiation of exposure film using the 5 × 5-mm collimator confirmed that the SARRP can deliver a collimated
beam of radiation with very limited scatter. The irradiated field was centered within ±0.25 mm on its isocenter.
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beam for a precalculated time interval to achieve the desired dose at a rate
of 1.65Gy/min using a 175-kV beam at 15mA, with a 0.15-mm copper
filter treating at 35-cm focus-to-skin distance.
Testing the accuracy of the CT-guided isocenter to predict the center
of the irradiated field. A 1-mm nylon fiducial bead was affixed to
Gafchromic EBT dosimetry exposure film (International Specialty
Products, Wayne, NJ) and CT scanned using the SARRP. The center
of the nylon fiducial marker was chosen as the isocenter for a 5 × 5-mm
square collimator that was used to deliver 3 Gy to the film. The exposed
area of film was evaluated to confirm that the center of the irradiated
field corresponded to the marked isocenter (Figure 2D).
Phosphorylation of histone protein H2AX staining. To confirm
precise localization of radiation to the intended target, immunohisto-
chemical staining for a marker of radiation damage, γH2AX, was per-
formed on ex vivo brain sections. One hour after radiation, the mouse’s
chest cavity was opened, and a continuous infusion of 1× PBS was
pumped into the left ventricle through an 18-gauge needle. A separate
incision in the right atrium allowed drainage of blood. The infusion
continued until the circulating fluid was clear, and then 10% neutral
buffered formalin was infused in the same manner. The animal was
allowed to fix for 5 minutes before the whole brain was removed
and postfixed in 10% formalin overnight. The brain was then placed
in 30% sucrose for 3 days and transferred to isopentane until frozen
(stored at −80°C). Tissue was sectioned coronally at 20-μm inter-
vals with a cryostat (MicromHM505 E;Microm,Walldorf, Germany)
and stained with antibodies against phosphorylated γH2AX, a histone
protein that is recruited to the site of double-strand breaks, as well as
4′,6-diamidino-2-phenylindole (DAPI) to visualize cell nuclei. These
immunohistochemical sections were then visualized with fluorescence
microscopy [9].
Assessing the effect of radiation on vascular permeability using
near-infrared fluorescent imaging. To measure the effects of radia-
tion on the vascular permeability of the tumor BBB, nude mice with
U251-GFP-Luc intracranial GBM tumors with or without targeted
cranial irradiation were imaged in vivo using the LI-COR Pearl near-
infrared fluorescent imager after injection of near-infrared polyethylene
glycol (PEG), a contrast agent designed to exploit the enhanced per-
meability and retention effect of leaky vascular endothelium. The
radiated group had tumors that were evenly matched in BLI signal
intensity. They received fractionated cranial irradiation (12 Gy in four
fractions) 23 days after tumor implantation. BLI was repeated 30 days
after radiation, and the BLI signal intensities of the tumors were used
to select matched controls from a cohort of previously unirradiated
mice with identically implanted intracranial tumors. Before fluorescent
imaging, mice were injected through tail vein with 100 μl (1 nmol) of
near-infrared PEG contrast agent (LI-COR’s IRDye 800 CW PEG).
In vivo fluorescent imaging was performed at intervals after injecting
the contrast agent (at 30 minutes and at 2, 24, and 36 hours) followed
by ex vivo imaging of the brain, liver, and blood 36 hours after injection
of the contrast agent.
Results
U251 Glioblastoma Mouse Model
We used U251 cells for our studies because it is a human GBM cell
line that, when implanted in mice, retains numerous characteristics
frequently observed in human tumors [10]. To track the growth of
these cells over time and to distinguish them from host tissues, the
U251 cells were transduced to express genes for luciferase and green
fluorescent protein (GFP) that enabled these cells to be readily detected
through BLI as well as by ex vivo fluorescent microscopy.
We confirmed that these implanted tumors recapitulated many
of the key features associated with glioblastoma, such as invasion
of adjacent brain tissue, necrosis, regions of hypoxia with increased
hypoxia-inducible factor (HIF-1α) expression, and increased vascular
endothelial growth factor (VEGF; Figure 1C ). The rapidly increas-
ing signal over time on BLI revealed that these implants consistently
demonstrated the high growth pattern expected with intracranial GBM
(Figure 1D).
We previously confirmed in vitro that the intensity of the bio-
luminescent signal was directly proportional to the number of viable
luciferase-expressing GBM cells [11]. In a pilot experiment using six
mice, a logarithmic best-fit test showed a strong correlation (R2 = 0.928)
between bioluminescent signal intensity and tumor volume determined
from in vivo MRI scans (Figure 1E). These studies established that our
animal model of GBM recapitulated clinical features of human tumors,
yet it was amenable to serial noninvasive BLI.
Image-Guided Stereotactic Delivery of Radiation to
Implanted Tumors
A cohort of nude mice with U251-GFP-Luc intracranial tumor im-
plants was imaged with BLI 18 days after implantation. BLI revealed
an intense area of signal limited to the site of tumor implantation with
an average maximum flux value of 1.30e + 09 photons/sec. Seven mice
had their discrete point of maximal BLI signal intensity determined as
described in the Materials and Methods section (Figure 2B) and were
then scanned using a spin-echo MRI protocol on a 9.4-T horizontal-
bore preclinical MR spectrometer to determine the precise anatomic
localization of their xenografts (Figure 2A). The point of maximal BLI
corresponded to the center of the tumor on MRI within ±0.5 mm in
any direction where the average maximal distance from the center of
the tumor to the tumor periphery was 1.7 mm and the average volume
for these tumors was 26.1 mm3.
Using Amira, we measured the dimensions of the tumor on coronal
MRI sections in one mouse with a representative tumor burden on
BLI (1.58e + 09 photons/sec) as 3.5 × 4.7 × 3 mm with a volume of
19.0 mm3 (Figure 2A). On the basis of these dimensions, a 5 × 5-mm
square collimator was selected to provide adequate coverage of the gross
tumor volume with an appropriate clinical margin while sparing nor-
mal surrounding brain. The mouse’s tumor was irradiated to 20 Gy
in a single fraction on the SARRP using the restrainer and fiducial
marker system described in theMaterials andMethods section (Figure 2,
C and D).
We had previously confirmed that the SARRP could deliver a
collimated beam of radiation with very limited scatter. Irradiation
of exposure film to 3 Gy using the 5 × 5-mm collimator resulted
in a sharply marginated, homogeneous, square pattern of exposure
with 5 × 5-mm dimensions that was centered within ±0.25 mm on
its isocenter (Figure 2E).
After delivery of the 20-Gy dose, γH2AX staining of the mouse’s
brain showed a well-demarcated volume of positive γH2AX staining
limited to the 5 × 5-mm radiation portal that successfully encompassed
the entire tumor volume (Figure 3).
To confirm the accuracy of our system for stereotactic radiation treat-
ment of mice brains, we irradiated the right hemisphere of a non–tumor-
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bearing mouse brain to 20 Gy using a rectangular collimator (7 × 2 mm;
Figure 3). The results of γH2AX staining on coronal brain sections
showed a clearly demarcated 2-mm band of positive γH2AX staining
that corresponded to the radiation portal. There was no evidence of
radiation injury on either side of the 2-mm field.
These results confirmed that we could accurately define the tumor
volume with our treatment planning process and could treat the
entire tumor precisely with our technique while sparing adjacent
normal tissue.
Evaluating the Novel Stereotactic SARRP
Immobilization Device
To confirm that our novel restraint does not introduce signal artifact
to the CT scanner, a CT scan of a mouse obtained with our stereotactic
cranial SARRP restrainer was compared to a CT scan of the same mouse
obtained with the standard restraint. The stereotactic brain restraint
introduced only minimal additional artifact, which did not affect image
resolution on the CT scan.
The novel stereotactic restraint resulted in no evidence of trauma to
the mouth or ear canals of animals who were placed in the restraint for
up to 50 minutes, equivalent to the time required to CT scan a mouse
in the treatment position and deliver 60 to 70 Gy in a single dose—
doses that would exceed the maximum clinically relevant dose for
brain irradiation. The animals showed no ill effects from the restraint
once they recovered from the anesthesia.
Targeted Radiation Results in Increased Permeability of the
Tumor BBB
Nude mice harboring orthotopic U251-GFP-Luciferase intracranial
GBM tumors evenly matched based on tumor bioluminescent signal
intensity were treated with 12 Gy in four fractions. BLI was repeated
30 days later, and the BLI signal intensities were used to select tumor-
matched controls from a cohort of untreated mice with implanted
intracranial tumors. Mice in both groups were then injected with a
near-infrared labeled PEG contrast imaging agent. To serve as addi-
tional controls, two separate cohorts of previously unirradiated nude
mice without tumors were injected with an equal volume of either
the near-infrared dye or PBS.
In vivo fluorescent imaging of the brains at 30 minutes and 2, 24,
and 36 hours after injection of the near-infrared dye revealed increased
signal in the irradiated tumors compared with the unirradiated tumors
at all time points (Figure 4). At 24 hours after injection, the irradiated
tumor group demonstrated a 1247% increase in the background-
corrected fluorescent signal compared with the mock-irradiated group
with tumor implants. As expected, mice treated with PBS alone had
no increased fluorescent signal in their brains. We confirmed that the
Figure 3. γH2AX staining of irradiated brain tissue confirms accurate delivery of stereotactic brain irradiation. Top row shows fluorescent
microscopy images of coronal brain sections from a mouse with an intracranial (forebrain) tumor (marked with arrows) killed 2 hours
after focal RT to 20 Gy in a single fraction using a 5 × 5-mm collimator, followed by staining for DAPI to visualize cell nuclei (left)
and γH2AX to visualize radiation-induced unrepaired double-strand breaks (right). γH2AX staining confirms the precise targeting of
the tumor using the described technique. The bottom row shows DAPI and γH2AX staining performed on coronal midbrain sections
of a mouse without intracranial tumor killed 2 hours after focal RT to 20 Gy × 1 using a 7 × 2-mm collimator with the long axis parallel to
the animal’s spine.
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increased fluorescent signal localized to the brain tumors rather than
to the surrounding normal brain tissue by ex vivo imaging of the har-
vested brains at 36 hours after injection. A comparison of the fluores-
cent signal from the extracted blood and ex vivo livers of all the mice
given the near-infrared contrast agent revealed comparable signal
intensities, suggesting that the different experimental results between
treatment groups could not be ascribed to variations in the vascular
concentration of the near-infrared contrast agent.
Interestingly, fluorescent signal from the mock-irradiated brain
tumors was significantly greater (P < .05) than the signal from the
normal brains of non–tumor-bearing control mice given the PEG con-
trast, suggesting that the presence of the implanted tumor resulted in
some baseline degree of increased permeability of the tumor BBB that
facilitated some extravasation of the contrast agent not observed in the
normal mouse brain with an intact BBB.
The finding that both the in vivo and the ex vivo fluorescent sig-
nals of the RT-treated tumors were higher than those of the mock-
irradiated tumors is consistent with the hypothesis that radiation
leads to increased disruption of the tumor BBB resulting in increased
extravasation of the contrast agent into the tumor.
Discussion
RT is a standard treatment for GBM as well as other brain and head
and neck cancers. Until the development of commercially available
small animal image-guided microirradiators like the SARRP, preclinical
research in these disease sites was limited by small animal radiation
techniques that lagged decades behind current clinical practice in the
precise targeting of tumor volumes and the sparing of normal tissue
[2,3]. Previously, only superficial tumors could be targeted with any
degree of precision using crude lead blocking to shield the surround-
ing normal tissue. The development of the SARRP has opened up
new avenues for preclinical RT research in these disease sites. The novel
stereotactic head restraint and fiducial marker targeting techniques
that we describe in this article offer an improvement on this technol-
ogy, with potential applications not only for preclinical brain irradia-
tion studies but also for studies involving any disease sites of the head
and neck.
The SARRP’s onboard CT scanner is limited in its ability to resolve
intracranial tumors for targeting purposes. While the bony anatomy of
the skull is well defined, allowing for easy identification of landmarks,
the xenografts themselves are not well demarcated (Figure 2D). Use of
a contrast agent can somewhat improve delineation of tumors, but our
early experimentation with this technique has so far been unsatisfying.
To supplement the limitations of the onboard CT scanner to visualize
brain tumors, we believe it is valuable to use MRI scans with long echo
time/long repetition time using thin slices to determine the tumor’s
location and dimensions for accurate targeting of the tumor.
While MRI is very good at defining tumor location and dimensions,
the absence of treatment planning software that allows CT/MRI fusion
somewhat limits the utility of MRI. BLI, although it cannot character-
ize the tumor’s dimensions with the accuracy of MRI, is useful because
the area of maximal BLI, which can be readily identified and marked
on the animal in real time, is a very good surrogate marker for the center
of the tumor as defined by MRI as we have demonstrated in our ex-
periments. Placement of a fiducial marker over the area of maximal BLI
signal can serve to confirm the location of the appropriate isocenter
immediately before delivering radiation treatments using an appropri-
ately sized collimator selected on the basis of the pretreatment MRI.
The development of an onboard bioluminescent imager for real-time
imaging when using the SARRP would greatly improve the efficiency
of treatment planning, tumor targeting, and treatment setup by obviat-
ing the need to place fiducial markers on the scalp corresponding to the
area of highest BLI signal.
As an illustration of the many potential applications of our SARRP-
based, image-guided RT delivery techniques using our mouse model
Figure 4. Targeted cranial RT for GBM orthografts is associated with increased extravasation of a near-infrared pegylated fluorescent
probe, thus indicating disruption of the tumor BBB. Mice with intracranial tumors of comparable sizes (confirmed by tumor BLI signal)
were irradiated through the SARRP (“RT,” 12 Gy in four daily fractions) or mock irradiated (“No RT”). After completion of RT, mice were
injected through the tail vein with LI-COR pegylated Near IR Dye. Serial in vivo fluorescent imaging revealed significantly increased
fluorescent signal in the irradiated brain tumors at all time points, indicating increased BBB disruption induced by the focused radiation
delivered. The group of three panels on the right (each labeled “Brain”) shows the tumor-containing irradiated (top) or mock-irradiated
(bottom) brains imaged after removal from the mouse (“ex vivo imaging”). The far right image confirms that increased BBB disruption
within the brain tumor corresponded to the RT field. The dashed box delineates the RT field, within which extravasation of near-infrared
fluorescent probe was maximal.
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of GBM, we performed a pilot study measuring the effect of stereo-
tactic cranial RT to disrupt the GBM tumor BBB. Several preclinical
and clinical studies have demonstrated that RT can cause focal dis-
ruption of the tumor BBB [12,13]. In our GBM mouse model, we
previously confirmed that cranial RT effectively disrupted the GBM
tumor BBB by showing that RT resulted in significantly greater IgG
extravasation into tumors compared with unirradiated tumors or irra-
diated normal brain tissue. The effects were durable, with increased
extravasation of IgG in the tumor still detectable by 35 days after RT
[11]. Using in vivo near-infrared fluorescent imaging to assess endo-
thelial permeability, we found that focal radiation of the tumor resulted
in significantly more extravasation of pegylated near-infrared contrast
agent into the tumor compared with unirradiated control tumors of
equal size, a finding that was confirmed on ex vivo fluorescent imaging.
This finding has implications for the use of targeted radiation to en-
hance delivery of cytotoxic agents that currently do not cross the tumor
BBB in sufficient concentration to produce a therapeutic effect. To
our knowledge, this pilot study is the first to use near-infrared in vivo
imaging using a pegylated fluorescent probe to assay tumor BBB per-
meability in response to a treatment intervention. We think this tech-
nique may be a promising avenue for additional research and validation
because in vivo fluorescent imaging using pegylated contrast agents is
more cost-effective, is more rapid, and requires less expertise than do
preclinical perfusion MRI studies such as dynamic contrast-enhanced
MRI. A major limitation to the use of the in vivo fluorescent probe
technique is that repeat injections of the fluorescent probe cannot be
performed at less than 10-day intervals because of the long half-life of
the agent in the circulation.
Our method of stereotactic irradiation of brain tumors applied to
our animal model system of GBM represents an improvement in the
ability of investigators to deliver precise radiation to carefully defined
targets in preclinical experiments. Future advances in the technology
of small animal microirradiator imaging and treatment planning,
including the ability not only to define an isocenter but also to con-
tour tumor volumes accurately using onboard imaging, will result
in further improvements. The future of clinically relevant preclinical
irradiation studies has never looked brighter.
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